Last reviewed 2026-06-01 · How we verify

Desflam (BUMADIZONE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Desflam (generic name: BUMADIZONE) is a bumadizone drug. It is currently in Phase 2 development.

Bumadizone works by inhibiting the growth of microorganisms.

Desflam is a small molecule with synonyms BUMADIZONA, BUMADIZONE, and BUMADIZONE.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUMADIZONE
Drug class	bumadizone
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a city, and microorganisms are like unwanted visitors. Bumadizone helps keep these visitors from multiplying and taking over by blocking their ability to grow and divide.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Desflam CI brief — competitive landscape report
Desflam updates RSS · CI watch RSS

Frequently asked questions about Desflam

What is Desflam?

Desflam (BUMADIZONE) is a bumadizone drug.

How does Desflam work?

Bumadizone works by inhibiting the growth of microorganisms.

What is the generic name of Desflam?

BUMADIZONE is the generic (nonproprietary) name of Desflam.

What drug class is Desflam in?

Desflam belongs to the bumadizone class. See all bumadizone drugs at /class/bumadizone.

What development phase is Desflam in?

Desflam is in Phase 2.

Drug class: All bumadizone drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing